Note to Affiliate: This document is based on the November 2023 Irish SmPC, the August 2020 J Tube IFU, the March 2019 NJ Tube IFU,  the August 2020 PEG IFU, the 2019 CADD Duodopa Patient Information Guide, and the February 2019 CADD Duodopa Pump Operator's Manual.



RESOURCES

Helpful resources and answers to some frequently asked questions about Duodopa

RESOURCES

Helpful resources and answers to some frequently asked questions about Duodopa


DOWNLOADS

The Duodopa System Video



Duodopa Daily Routines Video




Duodopa Snapshot Brochure



Frequently Asked Questions (FAQ)



General

 

[Placeholder for Affiliates to add local Important Treatment Considerations or remove]

The safety of Duodopa in patients under 18 years of age has not been established and its use in patients below the age of 18 is not recommended. There is a considerable experience in the use of levodopa/carbidopa in elderly patients. Doses for all patients including geriatric population are individually adjusted by titration.1

Duodopa should be given initially as monotherapy.1 If required, other medicinal products for Parkinson’s disease can be taken concurrently.1

There is no limit as to how long the tube can stay in the body.2,3  Based on clinical experience, the PEG tube can remain in place for many months without complications. In clinical trials, 82.1% of patients retained their original tubing at 24 months.2 Based on clinical experience, the J tube can remain in place for many months without complications. In clinical trials, 48.5% of patients retained their original tubing at 24 months.3

Yes. Treatment with Duodopa using a permanent tube can be discontinued at any time by withdrawing the tube and letting the wound heal. Treatment should then continue with oral medicinal products including levodopa/carbidopa.1

[Placeholder for Affiliates to add local information or remove]


Duodopa Initiation

 

Local guidelines should be followed. A temporary NJ tube should be considered to determine if the patient responds favorably to this method of treatment before a permanent PEG-J is placed. In cases where the physician considers this assessment is not necessary, the NJ test phase may be waived and treatment initiated directly with placement of the PEG-J.1 The morning dose and continuous maintenance dose should be based on the patient’s previous morning intake of levodopa and daily intake of levodopa, respectively.1

 

[Placeholder for Affiliates to add local information or remove]

 

The appropriate tubes will be provided [Placeholder for Affiliates to add local information or remove]

  • For the Duodopa delivery, AbbVie PEG (15 FR or 20 FR) and AbbVie J (intestinal tube 9 FR for PEG 15 and 20 FR) are used.2,3
  • For the nasojejunal test phase, AbbVie NJ 10 FR with stylet for enteral use only, are used.4

These tubes are equipped with a Luerlock connector to connect to the Duodopa cassette.

Local institutional protocol should be followed for antibiotic prophylaxis.2

No. The AbbVie J tube utilizes a Y-connector and click adapter assembly to connect the AbbVie PEG and AbbVie J tubes.2,3 The connector assembly has two ports that both utilize a proprietary reverse Luer connector system.


After Care

 

[Note to affiliate. Please check latest local versions or documents are used in any links in the FAQ section]

The PEG-J tube should be mobilized by pushing 3-4 cm into the stoma and moving back and forth every time the dressing is changed. When doing so the tube should not be turned or rotated under any circumstances to prevent the formation of loops and dislocation of the J tube.

Yes. Flush the PEG tube (via white “g” port) with at least 20 ml room temperature tap or drinking water daily. Failure to adequately flush the AbbVie PEG tube may result in occlusion or blockage.2


Pump Guidance & Operation

 

The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0).6 Full instructions on dose adjustment are given in the Operator’s Manual.5

Instructions for changing between the different lock levels can be found in the Operator’s Manual.5 Please note that the Duodopa pump must be locked again when it is handed back to the patient (i.e., lock level 1 or 2 [LL1 or LL2]).

Lock level, LL0 permits complete access to all programming and operating functions. The Duodopa pump may only be delivered to the patient when it is locked. There are 2 lock levels for this:

  • LL1 = partially locked:

– The patient can change the doses of the pump within a predetermined range.

  • LL2 = fully locked:

– The patient cannot change the doses.

 

The dose is programmed by the doctor in charge, and only doctors are supposed to make changes. Instructions for changing between the different lock levels and the instructions for changing the dose can be found in the Operator’s Manual.

Treatment is usually administered during the patient's awake period. If medically justified, Duodopa may be administered for up to 24 hours.1

No, the cassette can only be used for up to 24 hours once opened. The cartridges must be disposed of after use, even if they still contain residual gel. Do not reuse an opened cassette.1

This depends on the individual’s dosing needs. However, the maximum recommended daily dose is 200 ml of Duodopa (containing

4 g levodopa and 1 g carbidopa and is equivalent to two cassettes per day).1

Yes, that is possible. Duodopa is administered directly into the small intestine via the jejunal tube. As needed, enteral nutrition may be administered directly to the stomach in parallel with medication delivery to the intestine.

Yes, the Duodopa pump must be switched off and removed.5

Non-clinical testing has demonstrated that the AbbVie J is MR-conditional. A patient with this device can be safely scanned in an MRI system meeting the following conditions:

  • Static magnetic field of 1.5 Tesla and 3.0 Tesla only.
  • Maximum spatial gradient magnetic field of 1900 gauss/cm (19 T/m).
  • Maximum MRI system reported, whole body averaged specific absorption rate (SAR) of 4.0 W/kg (First Level Controlled Mode).

 

Under the scan conditions defined above, the AbbVie J tube is expected to produce a maximum temperature rise of 1.0°C after 15 minutes of continuous scanning.3

No, since the Duodopa pump is only splash-proof, it must be removed before showering or bathing.7 If necessary, an extra dose may be given beforehand to bridge the gap. The stoma should be dried well after bathing or showering.

The life of the batteries is dependent on the amount of Duodopa delivered, delivery rate, battery age, and the temperature. At the rate of 100 ml per day (one cassette), alkaline batteries will usually last about 7 days.5

[Placeholder for Affiliates to add local information]

No, rechargeable nickel cadmium (NiCd) or nickel metal hydride (NiMH) batteries or carbon zinc (‘heavy duty’) batteries should not be used. They do not provide sufficient power for the pump to operate properly.5 Therefore, only standard AA batteries should be used.


Complications, Warnings & Alarms

Please report all adverse events and adverse drug effects directly to our drug safety department. 

 

[Placeholder for Affiliates to add local information]

There may be a kink in the tubing or a clamp may be closed. Unkink the tubing or open the clamp and the pump will resume delivery.

Press ‘STOP/START or ‘NEXT‘ to stop the pump and silence the alarm for 2 minutes. After the cause of the high pressure has been removed, start the pump to continue delivery. If the alarm continues, the clinician responsible for the care should be contacted. 

 

[Placeholder for Affiliates to add local information]

 

In the clinical studies, complication of device insertion was a commonly reported adverse reaction for the PEG tube. This adverse reaction was co-reported with one or more of the following adverse reactions such as:1,2

 

  • Gastrointestinal disorders including abdominal pain, abscess, discomfort or distention, flatulence, pneumonia, pneumoperitoneum, duodenal ulcer, hemorrhage, intestinal ischemia, leakage of gastric fluid, gastritis erosive, pancreatitis, peritonitis or bleeding, intussusception, and sepsis
  • Buried bumper syndrome
  • Post-operative and post-procedural wound infection, incision site cellulitis or stoma infection
  • Procedural and post-procedural complications including discomfort, pain, incision site erythema, implant site erosion/ulcer, discharge, haemorrhage, gastrointestinal stoma complication or postoperative ileus
  • Skin and subcutaneous tissue disorders such as excessive granulation tissue

 

Abdominal pain may be a symptom of the above listed complications. Some events may result in serious outcomes, such as surgery and/or death. Patients should be advised to notify their physician if they experience any of the symptoms associated with the above events.6

 

 

[Note to affiliates. Please include adverse event reporting process directions as per your local rules and regulations]

 

If the upstream occlusion sensor is set to ‘ON’ and an occlusion in the Duodopa reservoir is detected, the upstream occlusion alarm will sound. Press ‘STOP/START’ or ‘NEXT‘ to stop the pump and silence the alarm for 2 minutes. You may have to detach then reattach the cassette.

 

Restart the pump to continue delivery.

 

If the alarm continues, contact your clinician.7

 

If you have any questions, or if the Duodopa system may be malfunctioning, please contact AbbVie. 

[Placeholder for Affiliates to add local information] 

 

[Note to affiliates. Please include product complaint reporting process directions as per your local rules and regulations.]


Everyday Life, Travelling & Carrier Systems

 

The Duodopa pump is only splash-proof, it must be removed before showering or bathing.7

 

[Placeholder for Affiliates to add local information]

For some patients, Duodopa may not work well if it is taken with, or shortly after eating, protein-rich food – such as meats, fish, dairy products, seeds and nuts.8

Duodopa must be refrigerated (2-8˚C) and the cassette should be kept in the outer carton in order to protect from light.1

Travel is possible. Patients must have treatment documentation and a cooler bag

 

[Placeholder for Affiliates to add local information]

Duodopa is approved in 48 countries worldwide. Before each trip abroad, it must be confirmed whether Duodopa will be available in the holiday country and whether the costs for prescriptions are borne by health insurance (this may have to be covered by travel health insurance).

Patients may need to check with the airport authorities to ensure that they follow the airport regulations for carrying the pump through security.



EVENTS

Details of forthcoming congresses at which AbbVie will be present

 
 
 
 
 

EVENTS

Details of forthcoming congresses at which AbbVie will be present

 

EVENTS 2024

10th European Academy of Neurology Congress
29 June - 2 July, 2024


International Congress of Parkinson's Disease and Movement Disorders
27 September - 1 October, 2024


[Placeholder for local DUODOPA indication and abbreviated safety information, as per local requirements]

[Placeholder for local DUODOPA SmPC, as per local requirements]

 

Please see Duodopa Summary of Product Characteristics for complete prescribing information.

[Please add local Summary of Product Characteristics Information to this link as per local requirements]

I want to receive more information via a product specialist


References

  1. Duodopa (levodopa/carbidopa intestinal gel) SmPC; [insert current data]
  2. AbbVie PEG information for users.
  3. AbbVie J information for users.
  4. AbbVie NJ information for users.
  5. Legacy Duodopa Operator’s Manual. CADD Legacy Duodopa Pump Model 1400.
  6. AbbVie. Duodopa PEG/J Aftercare Guideline. Risk Management Plan version 7.2.
  7. Legacy Duodopa Patient Information. CADD Legacy Duodopa Pump Model 1400.
  8. Duodopa patient information leaflet.